 |
|
|
| |
Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 µg: NEPTUNE study
|
| |
| |
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
YF Liaw,1 Q Xie,2 KH Han,3 EJ Gane,4 T Piratvisuth,5 P McCloud,6
C Wat,7 J Jia8
1. Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan;
2. Department of Infectious Diseases, Ruijin Hospital, Shanghai, China; 3. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea ; 4. Liver Unit, Auckland City Hospital, Auckland, New Zealand; 5. NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Hat Yai, Thailand; 6. Roche Products Pty Ltd, Dee Why, Australia;
7. Roche Products Ltd, Welwyn, UK; 8. Beijing Friendship Hospital, Capital Medical University, Beijing, China
|
| |
|
|
|
|
|
